|
FY2021
12 months to Sep 30, 2021
|
FY2020
12 months to Sep 30, 2020
|
FY2019
12 months to Sep 30, 2019
|
FY2018
12 months to Sep 30, 2018
|
FY2017
12 months to Sep 30, 2017
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net (loss) income | |||||
| Adjustments to reconcile Net (loss) income to net cash provided by operating activities: | |||||
| Impairment charges | |||||
| Realized loss on the sale of available-for-sale securities | |||||
| Depreciation and amortization | |||||
| Accretion on Asset Retirement Obligations | |||||
| Provision for doubtful accounts | |||||
| Deferred income tax benefit | |||||
| Share-based compensation expense | |||||
| Deemed repatriation transition tax | |||||
| Amortization of terminated interest rate swap contract | |||||
| Amortization of debt issuance costs | |||||
| (Gain) on sale of assets | |||||
| Loss (gain) on disposal of assets | |||||
| Non-cash foreign exchange loss (gain) | |||||
| Accretion and adjustment on Asset Retirement Obligations | |||||
| Non-cash charge on inventory step up of acquired inventory sold | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Acquisition of a business, net of cash acquired | |||||
| Additions to property, plant and equipment | |||||
| Proceeds from the sale of assets | |||||
| Cash settlement of life insurance policy | |||||
| Proceeds from the sales of assets | |||||
| Purchases of available-for-sale securities | |||||
| Proceeds from the sale and maturities of available-for-sale securities | |||||
| Settlement of net investment hedge | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Repurchases of common stock under Share Repurchase Program | |||||
| Dividends paid | |||||
| Proceeds from issuance of stock | |||||
| Repayment of long-term debt | |||||
| Repurchases of common stock withheld for taxes | |||||
| Debt issuance costs | |||||
| Proceeds from issuance of long-term debt | |||||
| Proceeds from revolving line of credit | |||||
| Repayment on revolving line of credit | |||||
| Other financing activities | |||||
| Net cash (used in) provided by financing activities | |||||
| Effect of exchange rate changes on cash | |||||
| (Decrease) increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for income taxes (net of refunds received) | |||||
| Cash paid for interest | |||||
| Purchases of property, plant and equipment in accrued liabilities and accounts payable at the end of the period | |||||
| Equity consideration related to the acquisition of KMG Chemicals, Inc | |||||
| KMG Chemicals, Inc. | |||||
| Total equity consideration related to the acquisition of KMG Chemicals, Inc | |||||
| Cash paid during the period for lease liabilities | |||||
| Right of use asset obtained in exchange for lease liabilities | |||||
Loading...